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pharmacological properties of zopiclone include anxiolytic, 
anticonvulsant, hypnotic, and myorelaxant properties. For 
these purposes, it is administered daily via the oral route. 
Such an administration lacks patient compliance and is 
very often associated with side effects because of crests 
and troughs in the plasma levels. On the other hand, a 
parenteral sustained release dosage form like biodegradable 
microspheres encapsulating zopiclone can lead to effective 
therapeutic levels and reduced side effects for this drug and 
thereby can enhance its therapeutic utility. Thus, in this 
study we aimed to develop a sustained release microsphere 
formulation for zopiclone using polycaprolactone as the 
biodegradable polymer. After preparation of microsphere 
INTRODUCTION
Zopiclone is a non-benzodiazepine, cyclopyrrolone 
derivative[1] with a chemical name [6-(5-chloropyridin-2-yl)-
5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl]4-methylpiperazine-
1-carboxylate. Zopiclone exerts its action by binding on 
the benzodiazepine receptor complex[1] and modulation of 
the GABABZ receptor chloride channel macromolecular 
complex. As it is non-benzodiazepine,[2] it is nonaddicting, 
less sedating with no physical, or physiological dependence. 
Most commonly seen side effects are taste alteration or 
dysgeusia (bitter, metallic taste, which is usually fleeting in 
most users), dry mouth, and headache. The therapeutic and 
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ABSTRACT
The aim of this study was to prepare zopiclone-loaded polycaprolactone microspheres by emulsion solvent 
evaporation technique with different drug-to-carrier ratios {MP 1 (1:1), MP 2 (1:2), MP 3 (1:3), and MP 4 (1:4)}, 
characterize and evaluate the in vivo performance. The microspheres were characterized for particle size, 
surface morphology, drug excipient compatibility, percentage yield, drug entrapment, and in vitro release kinetics. 
Pharmacokinetics and pharmacodynamics were evaluated after parenteral administration so as to determine the 
sustained action of the drug after one-time administration of the formulation in a rat model. Of four formulations 
prepared, MP 2, i.e., 1:2 (drug–polymer) ratio was selected as the optimized formulation based on particle size, 
particle shape, and the release behavior. The size of microspheres was found to be ranging from 5.4 to 12.1 
µm. The shape of microspheres was found to be spherical by SEM. Among the four formulations, MP 2 (1:2) 
showed maximum percentage yield of 75% ± 2.68%. There was no interaction between drug and polymer by 
FT-IR study. In the in vitro release study, formulation MP 2 (1:2) showed 86.5% drug release and was found to 
be sustained for 10 days. The microsphere formulations were able to sustain the release of drug both in vitro 
and in vivo. Pharmacodynamic study (Maze apparatus) indicated that the anxiolytic activity shown by zopiclone 
microspheres was significant when compared to the zopiclone solution given daily.
Key words: In vitro release, microspheres, pharmacodynamics, pharmacokinetics, polycaprolactone, 
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formulations using different drug–polymer ratios, the 
formulations were characterized for in vitro drug release, 
drug–polymer compatibility, size, and surface morphology.
The main objective of any drug therapy is to achieve a 
desired concentration of the drug in blood or tissue which 
is therapeutically effective and nontoxic for extended period 
of time, and this goal can be achieved by proper design of 
sustain release dosage regimen.[3,4] Thus, once we developed 
and characterized sustained release dosage forms using in 
vitro methods, we aimed to investigate its performance in an 
animal model. For this purpose, the developed microsphere 
formulations were administered via intraperitonial route, 
the pharmacokinetics and pharmacodynamics of the drug 
were investigated. The results are discussed.
MATERIALS AND METHODS
Materials
Polycaprolactone (average Mn: 60000; average Mw: 
80,000; MP: 60 °C) was purchased from Sigma-Aldrich, 
Germany. Zopiclone was a gift sample from Natco 
Pharma, Hyderabad. Polyvinylalcohol was purchased 
from Qualigens Fine Chemicals (New Delhi, India). 
Dichloromethane was purchased from Finar reagents. To 
conduct in vitro drug release studies, magnetic stirrer and 
cyclo mixer from Remi Equipments Pvt. Limited were used. 
A SL 164 Elico Double Beam UV–Vis spectrophotometer 
was used to analyze the samples. For separation of plasma 
from blood, centrifuge (Remi industries) was used. HPLC 
of Cyberlabs was used to analyze the drug. Diethyl ether 
was obtained from Finar Chemicals, Ahmedabad. Maze 
apparatus was used to evaluate the anxiolytic activity. 
The protocol of all experiments was approved by the 
institutional animal ethical committee. Male Wistar rats 
(100–150 g, 5 to 6 weeks old) purchased from animal 
center of Mahaveera enterprises whose Registration No. 
is 146per1999perCPSCEA, Hyderabad were used in this 
study.
Preparation of microspheres
Microspheres  of   zopiclone  using  biodegradable 
polycaprolactone as the polymer were prepared by 
emulsion–solvent evaporation method. Four different 
formulations MP 1, MP 2, MP 3, MP 4 containing drug–
polymer in the ratio of 1:1, 1:2, 1:3, and 1:4, respectively, 
were prepared. Dichloromethane (10 mL) was taken as 
organic phase in which polymer and drug were dissolved.[2] 
The drug content was always 100 mg in all the batches. The 
aqueous phase contained polyvinylalcohol PVA solutions in 
water at 2% w/v (30 mL). The organic phase was added to 
the aqueous phase drop by drop while the aqueous phase 
was kept for stirring on a magnetic stirrer. Stirring was 
continued till complete evaporation of dichloromethane 
occurred. As the organic phase evaporates, precipitation 
of the polymer and drug occurs due to which drug 
gets entrapped in the polymer and stirring results in 
size reduction as well as spherical particle formation. 
The microspheres, thus obtained were filtered through 
Wattmann filter paper number I, and the free unentrapped 
drug was also removed. Microspheres were air dried and 
used for further studies.
Physico-chemical evaluation of the microspheres
The microspheres prepared by emulsion solvent evaporation 
method[5] were evaluated for the following characteristics. 
The surface morphology and the internal textures of the 
microspheres were observed under scanning electron 
microscope. Particle size analysis was carried out using 
optical microscope ×40. About 50 particles were selected 
randomly, and their size was determined. Drug-excipients 
compatibility study[6] was carried out by the FTIR analysis 
of pure drug (zopiclone), pure polymer (polycaprolactone), 
microparticular system (zopiclone MS), and placebo 
microparticles (polycaprolactone MS). High-performance 
liquid chromatographic analysis was used for estimation 
of drug content.
In vitro release studies
The dialysis bag diffusion technique is widely used to 
evaluate drug release from micro- and nanosized carriers.[7]
This technique with the help of a dialysis membrane was 
used in this study. This membrane was then carefully 
clamped to one end of the hollow glass tube and 
considered as the donor compartment. The dissolution 
medium phosphate buffer pH (7.4)—50 mL was taken 
into the receiver compartment. The donor compartment 
was immersed into the receiver compartment so that the 
edge just touches the receiver compartment. An aliquot 
of 100 mg of the microparticles were dispersed in 1% 
NaCMC in phosphate buffered saline (PBS) solution 
and placed in the donor compartment. The rpm of the 
system was maintained at 50 by using magnetic stirrer and 
bead. Samples (5 mL) were removed from the receptor 
compartment and replaced with fresh medium immediately. 
These were analyzed by spectrophotometric method at 303 
nm wavelength.
Kinetics of  drug release[3]
In order to understand the mechanism and kinetics of 
drug release, the result of the in vitro dissolution study of 
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microspheres were fitted with various kinetic equations, 
such as zero-order (percentage release versus time), first-
order (log percentage of cumulative drug remaining versus 
time), Higuchi’s model (percentage drug release versus 
square root of time), and Korse Meyer Peppas model (log 
cumulative amount versus log time). Correlation coefficient 
(r2) values were calculated for the linear curves obtained by 
regression analysis of the above plots. Further, to confirm 
the mechanism of drug release, the first 60% of drug 
release was fitted in Korsemeyer–Peppas model with the 
equation: Mt/M∞. = Kt, where Mt/M∞ is the fraction of the 
drug release at time t, the n value is used to characterize 
different release mechanisms and is calculated for the slope 
of the plot of the log of fraction of drug released versus 
log of time (t).
Evaluation of pharmacokinetics of zopiclone in rats
The objective of this study was to determine the plasma 
concentration profile of zopiclone after administrations 
of its solution form after intravenous administration, 
suspension form after oral administration as well as in the 
microsphere form after intraperitoneal administration and 
evaluate the benefits of the microsphere formulation in 
terms of plasma concentration profile. In this study, the i.v. 
solution administration as well as i.v. oral administration are 
the references. The doses administered in the intravenous 
as well as oral administrations are equivalent doses to that 
administered in the form of microspheres. Microspheres 
containing 15 mg of zopiclone for prolonging the drug 
release in the plasma for 10 days with equivalent oral 
and i.v. dose of 15 mg were administered. The study was 
carried out on male Wistar rats weighing 100–150 g. After 
procurement of rats, these were acclimatized for 10 days 
prior to the conduction of the experiment. The animals 
were housed in clean cages and maintained in controlled 
temperature. They were fed with standard diet and ad 
libitum. Animals were divided into four groups. Each group 
contained four rats.
Group 1:  Received normal saline solution (0.9 mg/mL of 
NaCl) orally every day (1 mL/rat).
Group 2:  Received 15 mg of zopiclone suspension (1% 
NaCMC) orally.  
Group 3:  Received 15 mg of zopiclone solution by 
intravenous route.
Group 4:   Received zopiclone microspheres equivalent to 
15 mg of drug suspended in normal saline (0.9% 
w/v) solution intraperitonially on day 1.
Blood samples (0.5 mL) were collected from retro orbital 
sinus of rat eye under anesthesia at intervals of 1, 3, 6, 
12, and 24 h. For microparticular system, samples were 
collected after 24 h (i.e., day 1) day 2, day 3 till 10 days, 
respectively. The blood samples so collected were added 
to a series of graduated microcentrifuge tubes containing 
0.3 mL of sodium citrate solution (4% w/v in water). All 
the samples were centrifuged at 3000g for 10 min, and 
plasma was separated into other microcentrifuge tube by 
using micropipette and stored in deep freeze. The drug 
was extracted from the plasma by adding 500 µL of diethyl 
ether,[8] and vortexed on cyclo mixer for 20 min. The 
organic phase was separated and collected into another 
microcentrifuge tube and allowed to air dry by keeping the 
lid of the tube open for 24 h. These dried tubes were stored 
in deep freeze until HPLC analysis was performed. Before 
the HPLC analysis, samples were reconstituted with 50 µL 
of mobile phase (methanol–water, 40:60) and analyzed at 
304 nm wavelength. Prior to this, a HPLC standard curve 
for the drug in the plasma was generated. The mobile phase 
consisted of methanol–water at a ratio of 40:60.
Evaluation of pharmacodynamic (anxiolytic) activity 
of zopiclone
This study was designed to determine pharmacodynamic 
effects with the one time microsphere formulation and 
compare with daily administration of a similar dose. As 
a reason, the dose contained in the microspheres is for 
the entire 10 days (1.5 × 10 days =15 mg). The study was 
conducted on 16 Wistar rats, which were divided into four 
groups each group containing four rats. 
Group 1:  Served as normal control and received normal 
saline solution intraperitonially daily (1 mL/rat).
Group 2:  Served as standard and was given 0.5 mg/
kg of diazepam intraperitonially every day. 
The compound was dissolved in 0.9% saline 
by solubilization in one or two drops of 1 N 
HCl. Drug solution pH was then adjusted to 
approximately seven with 1 N NaOH. 
Group 3:  Received zopiclone solution at a dose of 1.5 mg 
daily for 10 days intraperitonially. The drug was 
dissolved in 0.9% saline by solubilization in one 
or two drops of 1 N HCl. Drug solution pH was 
then adjusted to approximately seven with 1 N 
NaOH.
Group 4:  Received zopiclone microspheres equivalent 
to 15 mg of drug suspended in normal saline 
(0.9%w/v) intraperitonially on day 1.
All the preparations, vehicle, or diazepam were administered 
by intraperitonial route 45 min before start of session. To 
start session rat was placed at the center of maze, its head 
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facing closed arm and allowed to explore for 5 min.[9,10] 
During this, 5 min time spent in open arm and number of 
entries in open arm were recorded. An entry was defined 
as all four paws on the arm.
RESULTS AND DISCUSSIONS
Polycaprolactone microspheres[11] of zopiclone were 
prepared by emulsion solvent evaporation technique. 
Polycaprolactone was selected as a polymer for the 
preparation of microspheres because of its biodegradable 
and biocompatible properties. Four different formulations 
MP 1, MP 2, MP 3, and MP 4 were prepared. Out of 
these formulations MP 2, i.e., 1:2 (drug–polymer) ratio 
was selected as the optimized formulation based on 
particle size, particle shape, and the release behavior. The 
microspheres were found to be spherical with quite smooth 
surfaces when viewed microscopically. Scanning electron 
microscopy of the microspheres showed that microspheres 
have spherical shape and discrete (PCL) [Figure 1]. The 
percentage yield was high for all the formulations and were 
in the range of MP 1 (50%), MP 2 (75%), MP 3 (72%), and 
MP 4 (74.5%), respectively. The particle sizes were differed 
due to variation in the composition of the formulation. 
Zopiclone was found to be compatible with the polymer 
in the microparticular formulation. This compatibility was 
concluded by comparing the FTIR profiles of pure polymer, 
pure drug, placebo biodegradable microparticles, and 
zopiclone biodegradable polycaprolactone microspheres. 
Spectra were shown in Figure 2. From the spectra, it was 
clear that there is no interaction between the drug zopiclone 
and polymer polycaprolactone at the end of fabrication of 
microspheres. Entrapment efficiency of the drug in MP1, 
MP2, MP3, and MP4 were found to be 32% ± 33%, 40% 
± 12.3%, 35% ± 5.5% and 28% ± 1.11%, respectively. The 
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Figure 1: SEM picture of zopiclone microspheres (magnification, 
×2000)
Figure 2: FTIR spectra (a) zopiclone; (b) polycaprolactone; (c) placebo 
microspheres; and (d) zopiclone microspheres
preparation method in this study was selected based on its 
suitability for poorly soluble drugs, and it was anticipated 
that the encapsulation would be appropriate using this 
methodology. Zopiclone is a poorly soluble drug. However, 
the encapsulation efficiencies were lower. This suggests that 
either the surfactant was not appropriate or enough drug 
was not partitioned into the polymer during the fabrication 
process. The state of art methodologies in such cases is 
to identify newer or appropriate surfactants and also to 
use polymers in which the drug is highly or appropriately 
encapsulated. If required newer methods of encapsulation 
such as o/o method, etc., might be of help. The objective 
of this study was to determine the feasibility of preparation 
of biodegradable parenteral microsphere formulations for 
zopiclone using solvent evaporation technique and perform J Young Pharm Vol 2 / No 3  227
the in vivo evaluation with the developed microspheres. 
In our subsequent studies, we would aim to improve the 
formulation aspects of zopiclone microspheres.
In vitro drug release from the zopiclone microspheres was 
carried out by dialysis membrane technique. The cumulative 
percent release of zopiclone from various formulations 
was shown in Figure 3. The cumulative drug release of 
various formulations was found to be MP 1 (63.5%), MP 
2 (86.4%), MP 3 (78.4%), and MP 4 (73.9%). The drug 
release from MP 1 was sustained for only 8 days and may 
be due to insufficiency of polymer to drug. In case of MP 
4, the drug release sustained for 18 days but cumulative 
percentage release was found to be less compared to MP 
2 due to high polymer content unabling the drug release 
probably because of drug binding to the polymer.
The drug–polymer ratio 1:2 showed better release pattern. 
It controlled the drug release for 10 days and was found to 
be the most suitable among other formulations.
The in vitro release data were applied to various kinetics 
models to predict the drug release mechanism and 
kinetics [Table 1]. The best-fit with the highest correlation 
coefficient was shown in Higuchi, first-order and followed 
by zero-order equations as given. The drug release 
mechanism from the microspheres thus can be described 
as diffusion controlled. The drug release was proportional 
to square root of time. When percentage of cumulative 
drug released versus time was plotted in accordance with 
first-order and zero-order equations, the r2 values obtained 
were found to be better for first-order plot compared to 
zero-order drug release, indicating that the drug release 
was described better with first-order release kinetics. The 
data obtained were also put in Korsmeyer–Peppas model in 
order to find out n value, which describes the drug release 
mechanisms. The n value of microspheres of different 
drug-to-polymer ratio was ranged between 0.23 and 0.54, 
indicating that the mechanism of drug release was diffusion 
controlled. The release also showed high correlation with 
the Korsmeyer–Peppas model. 
Drug levels in the plasma were determined using HPLC. 
The retention time of the drug was 9.2 min. The UV–
VIS detection wavelength was 304 nm. Plasma drug 
concentration versus time profile given in different routes 
were shown in Figure 4. Microspheres sustained the release 
of the drug up to 10 days, reflecting in an increased area 
under curve.
Anxiolytic activity[9,10] of zopiclone microspheres was 
evaluated using maze apparatus in which number of 
Parenteral sustained release microsphere formulation of zopiclone
Table 1: Value of r2 from release data of various 
formulations for different models of drug release
Model MP 1 MP 2 MP 3 MP 4
Zero-order
First-order
Higuchi
Korse Meyer 
Peppas
0.92
0.99
0.969
0.973
(n = 0.33)
0.91
0.97
0.987
0.982
(n = 0.25)
0.90
0.98
0.933
0.960
(n = 0.45)
0.84
0.94
0.869
0.894
(n = 0.55)
The values listed are the values of coefficient correlation (r2) obtained from release 
data of various formulations for different models of drug release, and n is the release 
exponent of Korsmeyer–Peppas model
Figure 3: In vitro drug release of zopiclone from microsphere 
formulations.
Figure 4: Plasma concentration time profile of zopiclone after oral, 
IV and IP administrations [Key: oral suspension administration; 
intravenous solution administration; intraperitoneal microsphere 
administration)
entries in open arm and time spent (s) in open arm were 
considered. The number of entries in open arm and time 
spent (s) in open arm were noted for standard diazepam 
administered daily through intraperitonial route, pure drug, 228   J Young Pharm Vol 2 / No 3
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Figure 5: The effects of diazepam, zopiclone, zopiclone microspheres 
on rats (open arm entries in rectangular maze)
Figure 6: The effects of diazepam, zopiclone, zopiclone microspheres 
on rats (time spent in open arm in rectangular)
i.e., zopiclone solution administered daily intraperitonially 
(10 mg/kg) and for zopiclone microspheres administered 
once starting day of the experiment [Figures 5 and 6]. All 
these results clearly indicate that the number of entries 
in open arm and time spent in open arm for zopiclone 
microspheres were significant when compared to the 
zopiclone solution given daily.
CONCLUSION
In this study, an attempt made to prepare zopiclone 
microspheres using a biodegradable, biocompatible 
carrier, polycaprolactone by emulsion solvent evaporation 
technique. The method was found to be simple and 
reproducible. These systems provide better therapeutic 
efficacy owing to continuous availability of drug in 
therapeutic ranges over a long period of time. Microspheres 
sustained the drug release both in vitro and in vivo. Data 
conveniently suggest that the microsphere formulation 
is more effective than the drug in conventional solution 
form. It may be concluded from the result obtained from 
evaluation that these systems are useful in achieving 
controlled drug release profile and help to reduce dose 
of the drug, dosing frequency, unwanted toxicities, and 
improved patient comfort and patient compliance. Thus, 
in this study a sustained release parenteral formulation of 
zopiclone has been developed and this formulation was 
evaluation both in vitro and in vivo for sustained release of 
the drug. 
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